DanCann Pharma A/S (NGM: DANCAN)

Market Cap	5.70M
Revenue (ttm)	12.17M
Net Income (ttm)	-87.83M
Shares Out	1.54B
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,443,777
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About DanCann Pharma

DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros. It is also involved in the import and distribution of Bedrocan CannGros, Bedica CannGros, and Bediol CannGros...

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Employees: 12
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: DANCAN

Financial Performance

In 2023, DanCann Pharma's revenue was 7.15 million, a decrease of -0.50% compared to the previous year's 7.19 million. Losses were -62.26 million, 287.6% more than in 2022.

Financial numbers in DKK